Very Positive Media Coverage Unlikely to Impact Arena Pharmaceuticals (ARNA) Share Price

Media stories about Arena Pharmaceuticals (NASDAQ:ARNA) have trended very positive this week, Alpha One reports. Alpha One, a division of Accern, identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arena Pharmaceuticals earned a media sentiment score of 0.52 on Alpha One’s scale. Alpha One also gave news coverage about the biopharmaceutical company an impact score of 39 out of 100, indicating that recent news coverage is unlikely to have an effect on the stock’s share price in the near future.

These are some of the news articles that may have effected AlphaOne Sentiment Analysis’s scoring:

Insider Buying and Selling by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)

Shares of Arena Pharmaceuticals (NASDAQ:ARNA) traded down 1.47% during midday trading on Wednesday, reaching $1.34. The company had a trading volume of 279,725 shares. Arena Pharmaceuticals has a 12-month low of $1.13 and a 12-month high of $2.02. The stock’s market capitalization is $425.36 million. The stock’s 50 day moving average is $1.31 and its 200-day moving average is $1.42.

Arena Pharmaceuticals (NASDAQ:ARNA) last issued its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.01. The company had revenue of $6.60 million during the quarter, compared to analysts’ expectations of $4.84 million. Arena Pharmaceuticals had a negative return on equity of 108.77% and a negative net margin of 19.07%. The business’s revenue for the quarter was down 33.0% compared to the same quarter last year. During the same period last year, the company earned ($0.09) earnings per share. On average, equities research analysts predict that Arena Pharmaceuticals will post ($0.34) earnings per share for the current fiscal year.

A number of brokerages recently issued reports on ARNA. Leerink Swann began coverage on Arena Pharmaceuticals in a research report on Friday, May 19th. They issued an “outperform” rating and a $5.00 target price on the stock. FBR & Co reissued an “outperform” rating and issued a $6.00 target price on shares of Arena Pharmaceuticals in a research report on Thursday, March 16th. Finally, Zacks Investment Research raised Arena Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 28th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $5.50.

ILLEGAL ACTIVITY WARNING: This article was originally published by sleekmoney and is the property of of sleekmoney. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at

In related news, insider Amit Munshi acquired 25,000 shares of the stock in a transaction dated Friday, May 12th. The stock was purchased at an average cost of $1.19 per share, with a total value of $29,750.00. Following the completion of the purchase, the insider now directly owns 76,875 shares in the company, valued at approximately $91,481.25. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 2.14% of the company’s stock.

Arena Pharmaceuticals Company Profile

Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Arena Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *